Respiratory · Bronchial Provocation TestingRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Provocholine (Methacholine Chloride) by Methapharm

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:31:37 AM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Provocholine signifies a positive regulatory development for Methapharm, potentially strengthening its market position in respiratory diagnostics. This could lead to increased competition in the bronchial provocation testing space, necessitating close monitoring of the approval timeline and market dynamics. Regulatory context from FDA (FDA AP — PROVOCHOLINE (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor the approval timeline and consider the implications for market share in respiratory diagnostics. The strongest clinical anchor is HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial (ClinicalTrials.gov), mechanism alignment (io ). In Respiratory · Bronchial Provocation Testing, 8 regulatory and 2 competitive items passed relevance filtering for Methapharm.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance Methapharm's position in the bronchial provocation testing market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROVOCHOLINE (SUPPL) (FDA). Entity match (methapharm).

Key Risks

Elevated medium regulatory exposure for Methapharm could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful approval could enhance Methapharm's market share in respiratory diagnostics, influencing revenue streams and competitive positioning against other players in the market.
Portfolio teams should monitor the approval timeline and consider the implications for market share in respiratory diagnostics.

What Would Change This Assessment

This becomes more urgent if Watch for updates on the approval process and any competitive responses from other companies in the respiratory space.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROVOCHOLINE (SUPPL)
FDAhigh relevance
Entity match (methapharm)
FDA document
View source
FDA AP — PROVOCHOLINE (SUPPL)
FDAhigh relevance
Entity match (methapharm)
FDA document
View source
FDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — VALACYCLOVIR HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

HFCWO Vest Plus Mechanical Cough Assist Versus Cough Assist Alone on Respiratory Infections in ALS: Pilot Trial
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Methapharm
Provocholine

Commercial impact

medium

Successful approval could enhance Methapharm's market share in respiratory diagnostics, influencing revenue streams and competitive positioning against other players in the market.

Regulatory impact

medium

The acceptance of the supplemental application indicates progress in the regulatory process, but further developments will be crucial to determine the final approval and any associated labeling changes.

What to watch

Watch for updates on the approval process and any competitive responses from other companies in the respiratory space.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.